<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415038</url>
  </required_header>
  <id_info>
    <org_study_id>PST2238-DM-03-010</org_study_id>
    <nct_id>NCT00415038</nct_id>
  </id_info>
  <brief_title>Efficacy of Rostafuroxin in the Treatment of Essential Hypertension</brief_title>
  <official_title>A Double Blind, Dose Range, Placebo Controlled Study of the Effects of Rostafuroxin vs Placebo in Patients With Stable, Uncomplicated, Essential Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>sigma-tau i.f.r. S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>sigma-tau i.f.r. S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of
      essential hypertension and to determine the best effective dose to be administered in the
      general hypertensive population and in a subset of this population in which genetic patterns
      could be involved in the etiology of essential hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated arterial pressure is probably the most important public health problem. about 30% of
      the world adult population are affected by hypertension in industrialised countries.
      Development of a pharmacogenomic approach to the therapy of primary hypertension give new
      opportunities for the treatment of hypertension. This approach consists in the identification
      of the genetic-molecular mechanisms responsible for hypertension in a given subset of
      patients, and in the development of drugs able to interfere with such mechanisms, thus
      leading to very selective therapeutic interventions with enhanced efficacy and reduced side
      effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Office Systolic Blood Pressure after 5 week of treatment</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office Diastolic Blood Pressure</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of normalised and responder patients (all visits)</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hours BP monitoring (through to peak ratio)</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on sub-populations, genetically selected</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of the drug</measure>
    <time_frame>monitored during all the study</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">438</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Rostafuroxin 50 micrograms capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rostafuroxin 150 micrograms capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rostafuroxin 500 micrograms capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rostafuroxin 1.5 mg capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rostafuroxin 5 mg capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rostafuroxin</intervention_name>
    <description>1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin</description>
    <arm_group_label>Rostafuroxin 50 micrograms capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rostafuroxin</intervention_name>
    <description>1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin</description>
    <arm_group_label>Rostafuroxin 150 micrograms capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rostafuroxin</intervention_name>
    <description>1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin</description>
    <arm_group_label>Rostafuroxin 500 micrograms capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rostafuroxin</intervention_name>
    <description>1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin</description>
    <arm_group_label>Rostafuroxin 1.5 mg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rostafuroxin</intervention_name>
    <description>1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin</description>
    <arm_group_label>Rostafuroxin 5 mg capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with grade 1 or 2 of essential hypertension

          -  Less than 3 risk factors (age &gt; 55 if male, smoking, dyslipidemia, family history of
             CV disease occurring before 55 years in men and 65 in women

          -  Naive patients or currently on monotherapy or one combination tablet

          -  SBP between 140 and 169 mmHg

        Exclusion Criteria:

          -  Atrial fibrillation or left or right VBBB

          -  Left ventricular hypertrophy

          -  Significant renal or hepatic disease

          -  Obesity &gt; 30kg/m2

          -  Diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan A Staessen, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Catholic University of Leuven, Laboratory of Hypertension Dept. of Molecular and cardiovascular Resesrach - Campus Gasthuisberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hilde Celis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Leuven Dept. of Molecular and cardiovascular Research, Laboratory of Hypertension</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kalina Kawecka-Jaszcz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University Medical College Krakow - I Cardiac Department - Krakow (Poland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bogdan Wyrzykowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hypertension and Diabetology - Medical Academy - Gdansk (Poland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrzej Tykarski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of hypertension - School of Medicine - Poznan (Poland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miroslaw Dluzniewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Medical School - Department of cardiology - Warszawa (Poland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrzey Januszewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine and Hypertension Warszawa (Poland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomasz Grodzicki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine and Gerontology - Jagiellonian University Medical College - Krakow (Poland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wieslawa Piwowarska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coronary Disease Department - Jagiellonian University medical College - Krakow (Poland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edoardo Casiglia, MD</last_name>
    <role>Study Director</role>
    <affiliation>IV Clinica Medica dell'Università di Padova, Dipartimento di Medicina Clinica e Sperimentale - Padova (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giancarlo Basso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.O. Cardiologia - Ospedale Civile di Schio (Vicenza) Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Manunta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Divisione di Nefrologia, Dialisi e Ipertensione - Ospedale S. Raffaele - Milano (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Glorioso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro per L'ipertensione A.S.L. n° 1 - Sassari (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianni Bellomo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Medicina Interna, Nefrologia e dialisi - Ospedale San Giovanni Battista - Foligno (Perugia) Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ezio Degli Esposti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unità di valutazione dell'efficacia clinica - Direzione Aziendale Ospedale S. Maria delle Croci - Ravenna (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuri Nikitin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of internal Medicine, Siberian Branch of the Russian Academy of Medical Sciences - Novosibirsk (Russia)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Viktor Milyagin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Postgraduate Education Faculty Smolensk State medical Academy - Smolensk (Russia)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergey Nedogoda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal and family Medicine - Volgograd (Russia)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Barton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Portiuncola Hospital Cardiac Research Department - Ballinasloe co Galway (Ireland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter W De Leeuw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Ziekenhuis Maastricht Afdeling Nefrologie - Mastricht (The Netherlands)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marielle ME Krekels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine/Nephrology Maaslandziekenhuis - Sittard (The Netherlands)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rock Accetto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical center, Hypertension Department - Ljubljana (Slovenia)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Hernandez-Menarguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de la Salud de Vistalegre - La Flota, Murcia (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose a Aleman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Salud Murcias San Andres - Murcia (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos c Gomez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario - Santiago de Compostela (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Pose-Reino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Conxo - Santiago de Compostela (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose M Pascual-Izuel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sagunto - Sagunto (Valencia) - Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep Redon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hipertension Clinic, Hospital Clinico University of Valencia - Valencia (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Coca-Payeras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico de Barcelona - Barcelona (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Filipovsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Derpartment of Internal Medicine 2, Faculty of Medicine - Pilsen (Czech Republic)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miroslav Soucek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine 2, St. Anne's Hospital, Faculty of Medicine - Brno (Czech Republic)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Burnier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division de Nephrologie, Department de Medecine, Centre Hopitalier Universitaire Vaudois - Lausanne (Switzerland)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University of Leuven - Laboratory of Hypertension, Dept. of Molecular and Cardiov. Research - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Staessen JA, Kuznetsova T, Acceto R, Bacchieri A, Brand E, Burnier M, Celis H, Citterio L, de Leeuw PW, Filipovský J, Fournier A, Kawecka-Jaszcz K, Manunta P, Nikitin Y, O'Brien ET, Redón J, Thijs L, Ferrari P, Valentini G, Bianchi G. OASIS-HT: design of a pharmacogenomic dose-finding study. Pharmacogenomics. 2005 Oct;6(7):755-75.</citation>
    <PMID>16207152</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>June 16, 2011</last_update_submitted>
  <last_update_submitted_qc>June 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Giovanni Valentini</name_title>
    <organization>Sigma Tau i.f.r. S.p.A.</organization>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>pharmacogenomic</keyword>
  <keyword>adducin</keyword>
  <keyword>ouabain</keyword>
  <keyword>rostafuroxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

